M. Johnson

Vamsidhar Velcheti, Philip J. Stephens, Vincent A. Miller, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC

Melissa L. Johnson, M. Agulnik, Melissa Johnson, 2013, OncoTargets and therapy.

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C.

Melissa L. Johnson, F. McCormick, C. Lindsay, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

P. Jänne, Melissa L. Johnson, S. Peters, 2015 .

Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Susan M. Chang, J. Meyerhardt, R. Schilsky, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

N. Reinmuth, Melissa L. Johnson, B. Cho, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

F. Bushman, Melissa L. Johnson, B. V. Van Tine, 2023, Nature Medicine.

Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer.

Melissa L. Johnson, R. Gentzler, M. Johnson, 2015, The oncologist.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).

B. B. Weitner, A. Rademaker, E. Hart, 2013 .

PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma

A. Hauschild, D. Schadendorf, C. Chung, 2018, The New England journal of medicine.

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.

B. Halmos, Melissa L. Johnson, J. Strauss, 2023, Clinical lung cancer.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

A. Iafrate, P. Stephens, A. Shaw, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.

Robert W. Hsieh, Melissa L. Johnson, J. Yang, 2022, The Lancet. Oncology.

Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

R. Govindan, T. Owonikoko, H. Borghaei, 2021 .

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

A. Drilon, B. Tuch, T. Mok, 2018, Journal of Thoracic Oncology.

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

A. Drilon, Keunchil Park, Melissa L. Johnson, 2018 .

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

R. Govindan, Melissa L. Johnson, E. Felip, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired Resistance to KRASG12C Inhibition in Cancer.

P. Jänne, D. Root, R. Heist, 2021, The New England journal of medicine.

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

R. Salgia, Melissa L. Johnson, R. Knoblauch, 2020, JTO clinical and research reports.

Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer.

Melissa L. Johnson, J. Patel, M. Johnson, 2014, Seminars in oncology.

Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings

Suzanne F. Jones, Melissa L. Johnson, L. Hart, 2016 .

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

C. Rudin, R. Govindan, Melissa L. Johnson, 2017, The Lancet. Oncology.

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Melissa L. Johnson, G. Weiss, I. Lowy, 2019, Clinical Cancer Research.

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

A. Shaw, Melissa L. Johnson, E. Felip, 2020, Targeted Oncology.

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

P. Jänne, R. Heist, J. Christensen, 2022, The New England journal of medicine.

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

A. Drilon, Keunchil Park, Y. Ohe, 2020, The New England journal of medicine.

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

A. Ghafoor, J. Tanyi, D. Oh, 2023, Nature Medicine.

Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.

Melissa L. Johnson, C. H. van der Leest, B. Cho, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FGFR3–TACC3: A novel gene fusion in cervical cancer

Emily Berry, Alvaro Restrepo, Melissa L. Johnson, 2015, Gynecologic oncology reports.

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

Ronglai Shen, Marc Ladanyi, M. Ladanyi, 2012, Clinical Cancer Research.

SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.

C. Rudin, Melissa L. Johnson, D. Brickman, 2020, Lung cancer.

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

N. Girard, M. Ahn, Melissa L. Johnson, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors.

Melissa L. Johnson, R. Gonzalez, A. Gollerkeri, 2017 .

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Melissa L. Johnson, P. Janne, Dong-Wan Kim, 2021, Cancer discovery.

Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.

Melissa L. Johnson, B. Besse, P. Garrido, 2020, Lung cancer.

Emerging targeted therapies for breast cancer.

Melissa L. Johnson, A. Seidman, Andrew D Seidman, 2007, Hematology/oncology clinics of North America.

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Y. Drew, J. Machiels, Melissa L. Johnson, 2019, Clinical Cancer Research.

Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers

M. Ladanyi, C. Sima, M. Kris, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

F. Cappuzzo, Michael Thomas, F. Shepherd, 2017, Lung cancer.

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

P. Jänne, S. Ou, J. Christensen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

B. B. Weitner, A. Rademaker, M. Kris, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2013, Cancer.

Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2012, Cancer.

Comparison of the KRAS/EGFR mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers.

M. Ladanyi, A. Drilon, C. Sima, 2012 .

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.

M. Ladanyi, C. Azzoli, Melissa L. Johnson, 2011, Lung cancer.

Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

C. Sima, M. Kris, C. Azzoli, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

P. Jänne, D. Root, R. Heist, 2021, Experimental and Molecular Therapeutics.

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017, The Lancet. Oncology.

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017 .

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.

P. Danaher, R. Sullivan, E. Schmidt, 2018 .

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

P. Jänne, S. Gettinger, F. Shepherd, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.

P. Jänne, Melissa L. Johnson, Channing Yu, 2019, Journal of Clinical Oncology.

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

D. Gandara, Melissa L. Johnson, S. Novello, 2022, Nature Medicine.

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Philip J. Stephens, James X. Sun, Garrett M. Frampton, 2016 .

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.

J. Nieva, Melissa L. Johnson, L. Byers, 2021, Journal of Clinical Oncology.

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

P. Jänne, S. Ou, R. Heist, 2021 .

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Robert W. Hsieh, Melissa L. Johnson, L. Paz-Ares, 2020 .

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial

C. Dooms, Melissa L. Johnson, S. Novello, 2023, The Lancet.

Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy

R. Sullivan, Melissa L. Johnson, M. Opyrchal, 2019, Clinical Trials.

ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.

E. Schmidt, Melissa L. Johnson, Douglas B. Johnson, 2018 .

Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.

Melissa L. Johnson, J. Wheler, A. Seidman, 2006, Seminars in oncology.

ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.

E. Schmidt, Melissa L. Johnson, M. Opyrchal, 2017 .

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

R. Coffman, Melissa L. Johnson, L. Bazhenova, 2021, Clinical Cancer Research.

A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT).

Melissa L. Johnson, G. Weiss, I. Lowy, 2016 .

524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis

P. Jänne, E. Gort, M. Lolkema, 2021, Annals of Oncology.

A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.

P. Jänne, E. Gort, K. Riemann, 2020 .

Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib

Melissa L. Johnson, L. Bazhenova, Jun Zhang, 2023, The oncologist.

Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

Jie Yang, C. Rudin, Melissa L. Johnson, 2023, Journal of Hematology & Oncology.

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.

Melissa L. Johnson, L. Byers, A. Navarro, 2021, Clinical lung cancer.

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

B. Taylor, M. Ladanyi, A. Drilon, 2020, Clinical Cancer Research.

Scientific Advances in Thoracic Oncology 2016.

H. Groen, C. Rudin, R. Rami-Porta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase 1 – 2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021 .

Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration

Melissa L. Johnson, J. Grilley-Olson, S. Hu-Lieskovan, 2021, Targeted Oncology.

P47.05 A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)

R. Heist, K. Yoh, A. Spira, 2021, Journal of Thoracic Oncology.

LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021, Annals of Oncology.

Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.

G. Giaccone, C. Azzoli, R. Govindan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).

F. Cappuzzo, F. Shepherd, A. Tsao, 2016 .

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

S. Ou, R. Heist, J. Christensen, 2022, Journal of Clinical Oncology.

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Ashutosh Kumar Singh, A. Drilon, K. Ching, 2023, Cancer Discovery.

Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.

Melissa L. Johnson, J. Grilley-Olson, S. Hu-Lieskovan, 2019, JAMA oncology.

OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy

Duc Minh Nguyen, P. Jänne, J. Neal, 2021, Journal of Thoracic Oncology.

LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC

P. Jänne, Melissa L. Johnson, M. Nishio, 2020 .

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.

Sonali M. Smith, R. Schilsky, H. Mackay, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Melissa L. Johnson, A. El-Khoueiry, J. Rodon, 2021, Clinical Cancer Research.

CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.

A. El-Khoueiry, H. Mamdani, A. Spira, 2020 .

A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.

T. Yap, G. Falchook, S. Parasuraman, 2021 .

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data

Lauren L. Ritterhouse, F. Cappuzzo, J. Lennerz, 2023, JCO oncology practice.

Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)

G. Linette, Melissa L. Johnson, M. Edelman, 2019, Clinical Trials.

Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non-small-cell lung cancer: support for the content validity of the 4-item Pulmonary Symptom Index.

D. Cella, Melissa L. Johnson, S. Magasi, 2013, Clinical lung cancer.

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of Thoracic Oncology.

Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer.

J. Patel, M. Johnson, 2014, Seminars in oncology.

Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

P. Jänne, Melissa L. Johnson, Dong-Wan Kim, 2021 .

A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)

G. Giaccone, T. Mok, Xiongwen Tang, 2016 .

LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer.

Jie Yang, A. Drilon, M. Tsuboi, 2022, Future oncology.

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

E. Smit, M. Ahn, Gregory Riely, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

N. Reinmuth, T. Mok, Melissa L. Johnson, 2021, Journal of Thoracic Oncology.

Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

G. Curigliano, D. Morgensztern, B. Besse, 2019, Journal of Clinical Oncology.

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Matthew J. Frigault, R. Govindan, Melissa L. Johnson, 2022, Journal for ImmunoTherapy of Cancer.

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers

C. Sima, M. Zauderer, M. Kris, 2016, PloS one.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)

M. Sznol, I. Puzanov, A. El-Khoueiry, 2022, Regular and Young Investigator Award Abstracts.

Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).

R. Govindan, R. Salgia, T. Owonikoko, 2019, Journal of Clinical Oncology.

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours

Suzanne F. Jones, Melissa L. Johnson, G. Fabbri, 2023, British Journal of Cancer.

G. Giaccone, C. Azzoli, R. Govindan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell‐based vaccines

Melissa L. Johnson, T. Gajewski, T. C. Manning, 2003, Journal of leukocyte biology.

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

A. Tolcher, R. Heist, F. Meric-Bernstam, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET: Topic: Phase II + NK

P. Jänne, D. Potvin, L. Cavanna, 2017 .

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study

K. Lewis, J. Goldman, S. Rothenberg, 2022, Clinical Cancer Research.

OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

R. Heist, F. Meric-Bernstam, K. Yoh, 2021 .

404 Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer

Melissa L. Johnson, N. Le, A. Naing, 2021, Journal for ImmunoTherapy of Cancer.

408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer

R. Wolff, N. Le, A. Naing, 2021, Journal for ImmunoTherapy of Cancer.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

P. Jänne, S. Ou, R. Heist, 2020 .

OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC

R. Govindan, A. Chiang, R. Salgia, 2021 .

A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

S. Ou, D. Potvin, J. Christensen, 2019, Journal of Clinical Oncology.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials Lung Cancer Coronavirus Disease Clinical

G. Scagliotti, H. Wakelee, T. Mitsudomi, 2022 .

1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)

Melissa L. Johnson, O. Gardner, H. Gilbert, 2020, Annals of Oncology.

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.

A. Chiang, A. Tolcher, D. Carbone, 2023, Journal of Clinical Oncology.

A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors.

Toshio Shimizu, J. Bendell, S. Piha-Paul, 2020 .

First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.

K. Kelly, Melissa L. Johnson, Huanyu Chen, 2019, Journal of Clinical Oncology.

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

Suzanne F. Jones, Melissa L. Johnson, J. Sachdev, 2023, Investigational New Drugs.